Drugs / MLN8054
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00652158 | Apr 2006 → Mar 2008 | cancer | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT00249301 | Oct 2005 → Jan 2008 | breast neoplasm, colonic neoplasm, pancreatic neoplasm, urinary bladder neoplasm | Millennium Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MLN8054 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00652158 ↗ |
| Action | Inhibit | “The levels of MLN8054 in the blood that are needed to inhibit Aurora A kinase.” NCT00249301 ↗1“Serine/threonine-protein kinase Aurora-A inhibitor” CHEMBL259084 ↗ |
| Modality | Small molecule | — CHEMBL259084 ↗ |
| Route | Oral | “administered orally” NCT00249301 ↗ |
| Target | AURKA | “Serine/threonine-protein kinase Aurora-A inhibitor” CHEMBL259084 ↗ |